Crohn’s Disease and Ulcerative Colitis (referred to as Inflammatory Bowel Disease, or IBD) are painful, debilitating autoimmune diseases which attack the digestive system and are, as yet, incurable.
More than 6.8 million people suffer from Crohn’s or Colitis around the world. Millions worldwide are affected by IBD, with this number increasing exponentially over the last several decades.
While several treatments exist and life expectancy is normal, many people with IBD receive suboptimal care with avoidable death, and the cause or causes of IBD remain unknown.
Crohn’s Colitis Cure’s (CCCs) purpose is to ‘transform patient outcomes’ in Inflammatory Bowel Disease (IBD) and be ‘instrumental in finding a cure’. CCC began its life as a charity in 2011 with a goal to create a technology asset that would make patient care more efficient, provide better outcomes for patients and clinicians, and develop a database which could be used to facilitate research into potential cures for Crohn’s Disease and Ulcerative Colitis.
It started with a small group of passionate physicians in the field of IBD from Australia and the United Kingdom, who could see there was a better way to address care needs for their patients. In conjunction with ANZIBDC, CCC requested tenders for the co-design and build of such a bespoke system.
What has followed over the last 10 years is the development of a cloud-based software tool (Crohn’s Colitis Care – CCCare), which benefits from very informed & bought-in clinical/community expertise in the initial and ongoing design.
This knowledge-based, physical “asset” (CCCare) differentiates us from most health-focused charities. It is this asset which enables ongoing collection, refresh and use of patient data for research into IBD.
Ongoing maintenance of CCCare requires funding, as does research into causes and possible cures for IBD. Government funding for disease specific support is extremely limited and public funding is insecure and uncertain. The need for donations is urgent and ongoing. Charitable donations are essential for us to can continue this work. We need your help to enable this important work to take place.m
CCC is at a ‘pivot point’ in its’ journey, having recently completed the development of a 3-year strategy aimed at transforming both our ambition and trajectory. In line with our stated purpose and ambition, we are moving from a primary focus on the ongoing development of our technology core, to placing the majority of our effort on the research component. We are in ongoing conversations to expand our partner base and welcome additional discussions from organisations who share our vision to transform patient outcomes and be instrumental in finding a cure to IBD.